Treatment of non-cystic fibrosis bronchiectasis

A method of reducing the frequency of pulmonary exacerbations in patients suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB) and P. aeruginosa infections, said method comprising:

• administering by inhalation to said patients a dose of from 20 mg Colistin Based Activity (CBA) as colistimethate sodium (CMS) a day to 60 mg CBA as CMS/day;
• and
• reducing said frequency of said pulmonary exacerbations in said patients, wherein said patients had at least two NCFB pulmonary exacerbations requiring oral or inhaled antibiotics or one NCFB pulmonary exacerbation requiring intravenous antibiotics in the 12 months preceding the inhalatory CMS administration and wherein said patients did not have any NCFB pulmonary exacerbation for at least 30 days before the beginning of the inhalatory CMS administration.